Study of four medicines for children with difficult blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 1 and 18 years old at first diagnosis (and under 21 at enrollment).
- You/your child must have had an appropriate cancer test on the tumor (molecular profiling and flow-cytometry) before joining.
- The cancer must have specific genetic features (like certain ABL1/PDGFRβ changes) or show a very deep lab drug-response result to dasatinib.
- Heart, kidney, liver, and blood vessel measurements must meet safety limits (including an ECG heart rhythm check).
- You must be able to swallow study pills (or the doctor can give them another permitted way).
- There must be no pregnancy/breastfeeding, no major drug allergy, and no major untreated infection (including hepatitis or HIV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
This trial tests a combination of three drugs (capivasertib, venetoclax, and dexamethasone) for children and young adults whose blood cancer has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
This trial studies a treatment approach for children and teens newly diagnosed with lymphoblastic lymphoma. It may help doctors choose therapies based on genetic risk information from lab testing done on tumor samples.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.